Merck stock trades steady as Keytruda drives double-digit revenue growth

Merck & Co., Inc. (ISIN US58933Y1055) remains one of the largest US pharmaceutical groups, and Merck stock is closely watched as oncology drug Keytruda becomes the dominant earnings driver. In full-year 2024, Merck reported total sales of around $63.1 billion, with Keytruda contributing approximately $25.0 billion, underlining how one product now accounts for roughly 40% of group revenue and continues to grow at a double-digit rate according to company disclosures. For investors, the balance between this concentration risk and Merck's broader portfolio and pipeline is central to the long-term story.

Keytruda revenue tops $25 billion

According to Merck's 2024 annual reporting materials, Keytruda sales reached about $25.0 billion in 2024, up from roughly $20.9 billion in 2023, an increase of around 19.6% year on year. This quantified comparison highlights how quickly the drug has expanded from a major franchise into the core pillar of Merck's revenue base. The therapy is approved across multiple cancer indications, including melanoma, lung, and head-and-neck cancers, and the company continues to pursue label expansions that can support further growth.

Beyond Keytruda, Merck reported that overall oncology revenue rose strongly in 2024, with oncology contributing more than half of pharmaceutical segment sales. The company also pointed out that Keytruda's growth was driven by increased demand in metastatic non-small cell lung cancer and additional indications, alongside continued geographic expansion. This concentration in oncology, while a strength today, means investors pay close attention to upcoming patent expiration timelines and any competitive pressures.

Revenue growth near double digits

Merck's total revenue of about $63.1 billion in 2024 represented an increase compared with 2023, when the company reported roughly $60.1 billion in sales, implying year-on-year growth of around 5%. While this is slower than the expansion of Keytruda alone, the comparison demonstrates that oncology is outgrowing the rest of the portfolio and lifting the company's top line. Excluding certain one-off items related to COVID-19 products, Merck highlighted that its underlying pharmaceutical business delivered closer to high-single-digit to low-double-digit growth, reflecting solid demand across oncology, vaccines, and hospital acute-care products.

Net income also improved versus the prior year as Keytruda's scale and relatively attractive margins supported earnings, although Merck continues to invest heavily in research and development. In 2024, the company allocated well over $13 billion to R&D, a level that underscores its commitment to sustaining a deep pipeline across oncology, vaccines, and cardiometabolic indications. The combination of robust cash generation from established franchises and sizable reinvestment into innovation is a key feature of the Merck equity story.

Pipeline and diversification beyond oncology

Merck emphasizes that, despite Keytruda's central role, its business model includes meaningful contributions from vaccines, hospital specialty products, and animal health. In recent reporting, the company highlighted strong demand for its human vaccines portfolio, including products in pediatric and adolescent immunization, which generated several billion dollars in annual revenue and grew at mid- to high-single-digit rates compared with the prior year. This diversification helps cushion Merck stock against potential volatility tied to a single oncology product.

The company also continues to invest in cardiometabolic and immunology assets. A number of late-stage pipeline candidates are in phase 3 trials, targeting conditions such as heart failure, chronic kidney disease, and autoimmune disorders. While these assets do not yet contribute materially to revenue, their future potential is part of why Merck maintains an elevated R&D budget and occasionally pursues targeted acquisitions and licensing deals to strengthen its portfolio. For equity holders, the timing and success of these programs can influence expectations around long-term growth once Keytruda eventually faces generic competition.

Keytruda supports Merck stock valuation

From an equity-market perspective, Keytruda's near-$25 billion annual sales and almost 20% year-on-year growth rate underpin a substantial share of Merck's valuation. Analysts often compare Merck's price-to-earnings and price-to-sales multiples with those of other large-cap pharmaceutical peers, noting that the company benefits from a relatively visible revenue trajectory in oncology but faces the usual sector risks around patent cliffs and regulatory developments. The fact that one product contributes roughly 40% of total revenue can be viewed both as a strength and a point to monitor carefully.

Merck's capital allocation policy further shapes how Merck stock is perceived. The company pays a recurring cash dividend and has a history of maintaining or modestly increasing payouts over time. Dividend payments in recent years have amounted to several billion dollars annually, funded by operating cash flow that also supports R&D and selective share repurchases. For income-oriented investors, the combination of a cash yield and exposure to oncology-led growth makes Merck a notable name within the large pharmaceutical universe, even as it shares sector-wide sensitivity to policy changes and drug-pricing debates.

Keytruda and oncology franchise

Keytruda is a programmed death receptor-1 (PD-1) blocking antibody and has become Merck's flagship oncology product. The drug's expanding label means it is prescribed across a broad spectrum of tumor types and stages, and Merck continues to run clinical studies that test Keytruda both as monotherapy and in combination with other agents. Each successful indication expansion tends to increase the addressable patient population, which has been a direct driver of the near-20% revenue rise from about $20.9 billion in 2023 to roughly $25.0 billion in 2024.

The oncology franchise also includes other products that, while smaller than Keytruda, contribute to the overall therapeutic offering. These include agents for hematologic malignancies and supportive therapies used alongside primary cancer treatments. Merck's strategy in oncology focuses on maintaining Keytruda's position while layering in new mechanisms of action that can drive future growth once current blockbusters reach maturity. As a result, the company invests significantly in oncology-focused clinical trials and partnerships, which in turn influence sentiment around Merck stock when new data read-outs are expected.

Merck stock and recent performance

Merck shares are listed on the New York Stock Exchange under the ticker symbol MRK, and Merck stock forms part of major US equity benchmarks such as the S&P 500. Over the past year, the stock price has broadly reflected investors' assessment of ongoing Keytruda growth, pipeline developments, and general market conditions including interest-rate trends and sector rotation into or out of defensive healthcare names. The company's market capitalization has consistently remained in the tens of billions of dollars, confirming its status as a large-cap pharmaceutical issuer with deep liquidity.

For many market participants, relative valuation against other large pharmas is an important lens. Merck's growth profile, dominated by oncology, contrasts with some peers that rely more on immunology or diabetes franchises. When Keytruda's nearly 20% annual revenue growth is combined with Merck's overall 5% top-line increase between 2023 and 2024, the company appears positioned somewhere between purely mature pharma and high-growth biotech. This hybrid profile can make Merck stock attractive to investors seeking a blend of stability and growth potential, though it also means Merck is exposed to both structural healthcare risks and cyclical macro factors.

Representative product focus

Keytruda is the clearest representative product for understanding Merck's current corporate trajectory. The drug is indicated for multiple cancers and has received approvals across major markets, including the United States, Europe, and Asia. Its mechanism of action, targeting the PD-1 pathway, has been central to the wave of immuno-oncology treatments that have reshaped cancer care in the past decade. The near-$25.0 billion annual sales figure in 2024 not only underscores its commercial success but also highlights the degree to which Merck's R&D, marketing, and clinical strategy revolve around this asset.

Because of this, Merck invests heavily in post-marketing studies, real-world evidence gathering, and new trial designs that can further differentiate Keytruda from competing agents. Pricing and reimbursement negotiations with healthcare systems and insurers are critical to maintaining access and revenue levels, and regulatory bodies continue to monitor safety and effectiveness as usage expands. The drug's prominence means that regulatory decisions, new safety data, or competitive entries into key indications can all have meaningful effects on expectations for Merck stock.

Merck stock price context

On major US exchanges, Merck stock trades in US dollars and benefits from high daily liquidity, reflecting the breadth of its shareholder base. The stock has historically exhibited less volatility than many smaller biotech names, in part because Merck's diversified revenue streams and established portfolio offer a degree of stability. Nonetheless, price movements can still be sizable around key events such as quarterly earnings releases, major pipeline updates, or policy decisions affecting drug pricing.

Investors often monitor Merck's share price relative to its 52-week range and broader index performance. When Keytruda's revenue growth of nearly 20% and total company revenue growth of around 5% in 2024 are taken into account, the valuation of Merck stock reflects both current cash-flow strength and the discounted impact of future patent expirations and new product launches. The interplay between these factors, alongside broader macroeconomic conditions, will continue to shape how the market prices Merck over time.